Expression and Correlation of IL-2, IL-10 and TNF-α in Patients with Multiple Myeloma-infected Herpes Zoster Treated by Bortezomib-containing Regimen

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2022 Jan 17

PMID 35035711

Authors

Kang Liu

Yafei Yin

Xinfu Zhou

Kaibo Zhu

Zimian Luo

Affiliations

Soon will be listed here.

Abstract

Background: Multiple myeloma (MM) is a proliferative disease with complex pathogenesis. Most patients will have low body resistance and high inflammatory mediators. Bortezomib is an anti-tumor drug. There are few reports on the clinical efficacy and adverse reactions of bortezomib intervention. This research aimed to explore the effect of bortezomib on inflammation and immune lymphocytes of patients with MM-infected herpes zoster.

Objective: The aim of this study is to explore the effect of bortezomib on inflammation and immune lymphocytes, i.e. the expression and correlation of interleukin (IL)-2, IL-10 and tumor necrosis factor-α (TNF-α) in patients with MM-infected herpes zoster (HZ) receiving bortezomib-containing regimen.

Methods: From October 2017 to March 2020, 83 MM patients receiving bortezomib-containing regimen were analyzed retrospectively, patients were divided into infection group (28 cases, IG) and non-infection group (55 cases, NG) based on whether or not they are complicated with HZ Pre- and post-treatment. IL-2, IL-10, TNF-α and immune lymphocytes (CD3, CD4, CD8) were tested by AimPlex multifactor flow detection technique, and the Eastern Cooperative Oncology Group (ECOG) performance status scores were compared before therapy. The independent risk factors of patients receiving bortezomib-containing regimen were analyzed via multivariate logistic regression.

Results: After therapy, serum IL-2 and TNF-α declined significantly in NG while changed insignificantly in IG. Compared with NG, serum CD3 and CD4 in IG increased after treatment, while CD8 decreased significantly. Before therapy, ECOG score in IG was higher than that in NG. Correlation analysis showed that IL-2 and TNF-α were negatively correlated with CD3 and CD4, and positively correlated with CD8 and ECOG score. IL-10 was the opposite. Multivariate logistic regression analysis identified the independence of declined CD3, CD4, CD8 and IL-10, increased IL-2, TNF-α and ECOG score before treatment as risk factors for HZ.

Conclusion: MM patients have a high incidence of HZ. Before treatment, lymphocytopenia, increased IL-2, TNF-α and decreased IL-10 are important risk factors for HZ.

Citing Articles

Early Diagnosis of Herpes Zoster Neuralgia: A Narrative Review.

Fan H, Zhang E, Fei Y, Huang B, Yao M Pain Ther. 2023; 12(4):893-901.

PMID: 37129752 PMC: 10289968. DOI: 10.1007/s40122-023-00510-4.

Proposed new prognostic model using the systemic immune-inflammation index for primary central nervous system lymphoma: A prospective-retrospective multicohort analysis.

Li S, Xia Z, Cao J, Zhang J, Chen B, Chen T Front Immunol. 2022; 13:1039862.

PMID: 36439151 PMC: 9681794. DOI: 10.3389/fimmu.2022.1039862.

References

Khalafallah A, Woodgate M, Koshy K, Patrick A . Ophthalmic manifestations of herpes zoster virus in patients with multiple myeloma following bone marrow transplantation. BMJ Case Rep. 2013; 2013. PMC: 3603998. DOI: 10.1136/bcr-2012-007625. View

Levin M, Weinberg A, Schmid D . Herpes Simplex Virus and Varicella-Zoster Virus. Microbiol Spectr. 2016; 4(3). DOI: 10.1128/microbiolspec.DMIH2-0017-2015. View

Ramsenthaler C, Osborne T, Gao W, Siegert R, Edmonds P, Schey S . The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study. BMC Cancer. 2016; 16:427. PMC: 4937527. DOI: 10.1186/s12885-016-2410-2. View

Gershon A, Brooks D, Stevenson D, Chin W, Oldstone M, Gershon M . High Constitutive Interleukin 10 Level Interferes With the Immune Response to Varicella-Zoster Virus in Elderly Recipients of Live Attenuated Zoster Vaccine. J Infect Dis. 2018; 219(8):1338-1346. PMC: 6601527. DOI: 10.1093/infdis/jiy660. View

Bazyka D, Gudzenko N, Dyagil I, Trotsiuk N, Gorokh E, Fedorenko Z . Incidence of multiple myeloma among cleanup workers of the Chornobyl accident and their survival. Exp Oncol. 2017; 38(4):267-271. View

Kritikos N, Priftakis D, Stavrinides S, Kleanthous S, Sarafianou E . Nuclear medicine techniques in Merkel cell carcinoma: A case report and review of the literature. Oncol Lett. 2015; 10(3):1610-1616. PMC: 4533682. DOI: 10.3892/ol.2015.3377. View

Xie H, Gu Y, Wang W, Wang X, Ye X, Xin C . Silencing of SENP2 in Multiple Myeloma Induces Bortezomib Resistance by Activating NF-κB Through the Modulation of IκBα Sumoylation. Sci Rep. 2020; 10(1):766. PMC: 6972929. DOI: 10.1038/s41598-020-57698-0. View

Bataille R . The multiple myeloma bone eco-system and its relation to oncogenesis. Morphologie. 2015; 99(325):31-7. DOI: 10.1016/j.morpho.2015.03.002. View

Das R, Strowig T, Verma R, Koduru S, Hafemann A, Hopf S . Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice. Nat Med. 2016; 22(11):1351-1357. PMC: 5101153. DOI: 10.1038/nm.4202. View

10.

Krejcik J, Casneuf T, Nijhof I, Verbist B, Bald J, Plesner T . Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016; 128(3):384-94. PMC: 4957162. DOI: 10.1182/blood-2015-12-687749. View

11.

Robak P, Robak T . Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later. Drugs R D. 2019; 19(2):73-92. PMC: 6544598. DOI: 10.1007/s40268-019-0269-9. View

12.

Zhu S, Chen H, Wang M, Xu Y, Quan R, Ding X . [Level of Regulatory B Cells in Patients with Immune Thrombocytopenia and Its Clinical Significance]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019; 27(1):175-179. DOI: 10.7534/j.issn.1009-2137.2019.01.028. View

13.

Demirelli B, Babacan N, Ercelep O, Ozturk M, Kaya S, Tanrikulu E . Modified Glasgow Prognostic Score, Prognostic Nutritional Index and ECOG Performance Score Predicts Survival Better than Sarcopenia, Cachexia and Some Inflammatory Indices in Metastatic Gastric Cancer. Nutr Cancer. 2020; 73(2):230-238. DOI: 10.1080/01635581.2020.1749290. View

14.

Liu W, Ren H, Dong Y, Wang L, Yin Y, Li Y . Bortezomib regulates the chemotactic characteristics of T cells through downregulation of CXCR3/CXCL9 expression and induction of apoptosis. Int J Hematol. 2012; 96(6):764-72. DOI: 10.1007/s12185-012-1195-6. View

15.

Peng L, Du B, Sun L, Zhao Y, Zhang X . Short-term efficacy and safety of prednisone in herpes zoster and the effects on IL-6 and IL-10. Exp Ther Med. 2019; 18(4):2893-2900. PMC: 6755452. DOI: 10.3892/etm.2019.7898. View

16.

Gerecke C, Fuhrmann S, Strifler S, Schmidt-Hieber M, Einsele H, Knop S . The Diagnosis and Treatment of Multiple Myeloma. Dtsch Arztebl Int. 2016; 113(27-28):470-6. PMC: 4973001. DOI: 10.3238/arztebl.2016.0470. View

17.

van de Donk N, Usmani S . CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance. Front Immunol. 2018; 9:2134. PMC: 6158369. DOI: 10.3389/fimmu.2018.02134. View

18.

Landgren O, Lu S, Hultcrantz M . MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment. Semin Hematol. 2018; 55(1):44-50. DOI: 10.1053/j.seminhematol.2018.03.001. View

19.

Kibata K, Ito T, Inaba M, Tanaka A, Iwata R, Inagaki-Katashiba N . The immunomodulatory-drug, lenalidomide, sustains and enhances interferon-α production by human plasmacytoid dendritic cells. J Blood Med. 2019; 10:217-226. PMC: 6635835. DOI: 10.2147/JBM.S206459. View

20.

Pandit A, Leblebjian H, Hammond S, Laubach J, Richardson P, Baden L . Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation. Bone Marrow Transplant. 2018; 53(7):942-945. DOI: 10.1038/s41409-018-0112-x. View